Sandbox g23: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
Line 188: | Line 188: | ||
:* Helminths | :* Helminths | ||
::* | ::* '''Baylisascaris procyonis''' | ||
:::* Preferred regimen: [[ | :::* Preferred regimen: [[Albendazole]] {{and}} [[Diethylcarbamazine]] {{and}} [[Corticosteroids]] | ||
::* | |||
::* '''Gnathostoma''' | |||
:::* Preferred regimen: [[Albendazole]] {{or}} [[Ivermectin]] | :::* Preferred regimen: [[Albendazole]] {{or}} [[Ivermectin]] | ||
::* | |||
:::* Preferred regimen: [[Albendazole]] {{ | ::* '''Taenia solium (cysticercosis)''' | ||
:::* Alternative regimen: [[Praziquantel]] | :::* Preferred regimen: [[Albendazole]] {{and}} [[Corticosteroids]] | ||
:::* Alternative regimen: [[Praziquantel]] {{and}} [[Corticosteroids]] | |||
:* Prion | :* Prion | ||
::* '''Human transmissible spongiform encephalopathy''' | ::* '''Human transmissible spongiform encephalopathy''' | ||
:::* Preferred regimen: supportive | :::* Preferred regimen: supportive |
Revision as of 04:50, 7 June 2015
Encephalitis
- Pathogen-directed antimicrobial therapy[1]
- Viruses
- Adenovirus
- Preferred regimen: supportive
- B virus (herpes B virus)
- Established disease
- Preferred regimen: Valacyclovir 1,000 mg PO tid OR Ganciclovir 5 mg/kg IV q12h for ≥ 14 days until resolution of neurologic symptoms, then Acyclovir 800 mg PO 5 times daily indefinitely OR Valacyclovir 1 g PO tid indefinitely
- Alternative regimen: Acyclovir 15 mg/kg IV q8h for ≥ 14 days until resolution of neurologic symptoms, then Acyclovir 800 mg PO 5 times daily OR Valacyclovir 1 g PO tid indefinitely
- Prophylaxis after bite or scratch
- Preferred regimen: Valacyclovir 1,000 mg PO tid
- Cytomegalovirus (CMV)
- Preferred regimen: Ganciclovir 5 mg/kg IV q12h for 14–21 days, followed by 5 mg/kg IV qd for maintenance AND Foscarnet 90 mg/kg IV q12h for 14–21 days, followed by 90-120 mg/kg IV qd for maintenance
- Eastern equine encephalitis virus
- Preferred regimen: supportive
- Epstein-Barr virus (EBV)
- Preferred regimen: supportive ± Corticosteroids
- Note: Acyclovir is not recommended.
- Hendra virus
- Preferred regimen: supportive
- Human herpesvirus 6 (HHV-6)
- Preferred regimen: Ganciclovir 5 mg/kg IV q12h for 14–21 days, followed by 5 mg/kg IV qd for maintenance OR Foscarnet 90 mg/kg IV q12h for 14–21 days, followed by 90-120 mg/kg IV qd for maintenance
- Human immunodeficiency virus (HIV)
- Preferred regimen: HAART
- Influenza virus
- Preferred regimen: Oseltamivir 75 mg PO bid
- Japanese encephalitis virus
- Preferred regimen: supportive
- Note: Interferon alpha is not recommended.
- JC virus
- Preferred regimen: Reversal or control of immunosuppression OR HAART in patients with AIDS
- La Crosse virus
- Preferred regimen: supportive
- Mumps virus
- Preferred regimen: supportive
- Murray Valley encephalitis virus
- Preferred regimen: supportive
- Nipah virus
- Preferred regimen: supportive
- Alternative regimen: Ribavirin
- Nonpolio enteroviruses
- Preferred regimen: supportive
- Note: Consider intraventricular γ-globulin for chronic and/or severe disease.
- Poliovirus
- Preferred regimen: supportive
- Powassan virus
- Preferred regimen: supportive
- Rabies virus
- Preferred regimen: supportive
- Note: Administer rabies immunoglobulin and vaccination for postxposure prophylaxis.
- Rubella virus
- Preferred regimen: supportive
- St. Louis encephalitis virus
- Preferred regimen: supportive
- Alternative regimen: IFN-α-2b
- Tickborne encephalitis virus
- Preferred regimen: supportive
- Vaccinia
- Preferred regimen: supportive ± Corticosteroids (if suggestive of post-immunization)
- Venezuelan equine encephalitis virus
- Preferred regimen: supportive
- Varicella zoster virus (VZV)
- Preferred regimen: Acyclovir 10–15 mg/kg IV q8h for 10–14 days ± Corticosteroids
- Alternative regimen: Ganciclovir 5 mg/kg IV q12h for 14–21 days, followed by 5 mg/kg IV qd for maintenance ± Corticosteroids
- West Nile virus
- Preferred regimen: supportive
- Western equine encephalitis virus
- Preferred regimen: supportive
- Bacteria
- Anaplasma phagocytophilum (human granulocytotrophic ehrlichiosis)
- Preferred regimen: Doxycycline
- Bartonella bacilliformis (Oroya fever, Carrion's disease)
- Preferred regimen: Chloramphenicol OR Ciprofloxacin] OR Doxycycline OR Ampicillin OR Trimethoprim-Sulfamethoxazole
- Bartonella henselae (cat scratch disease)
- Preferred regimen: Doxycycline OR Azithromycin ± Rifampin
- Borrelia burgdorferi (Lyme disease)
- Preferred regimen: Ceftriaxone OR Cefotaxime OR Penicillin G
- Coxiella burnetii (Q fever)
- Preferred regimen: Doxycycline AND Fluoroquinolone AND Rifampin
- Ehrlichia chaffeensis (human monocytotrophic ehrlichiosis)
- Preferred regimen: Doxycycline
- Listeria monocytogenes
- Preferred regimen: Ampicillin AND Gentamicin
- Alternative regimen: Trimethoprim-Sulfamethoxazole
- Mycobacterium tuberculosis
- Preferred regimen: (Isoniazid AND Rifampin AND Pyrazinamide AND Ethambutol) ± Dexamethasone (if suggestive of meningitis)
- Mycoplasma pneumoniae
- Preferred regimen: Azithromycin OR Doxycycline OR Fluoroquinolone
- Rickettsia rickettsii (Rocky Mountain spotted fever)
- Preferred regimen: Doxycycline
- Alternative regimen: Chloramphenicol (for pregnant patients)
- Treponema pallidum (syphilis)
- Preferred regimen: Penicillin G
- Alternative regimen: Ceftriaxone
- Tropheryma whipplei (Whipple's disease)
- Preferred regimen: Ceftriaxone for 2–4 weeks, followed by Trimethoprim-Sulfamethoxazole for 1–2 years OR Cefixime for 1–2 years
- Fungi
- Coccidioides
- Preferred regimen: Fluconazole
- Alternative regimen: Itraconazole OR Voriconazole OR Amphotericin B (intravenous and intrathecal)
- Cryptococcus neoformans
- Preferred regimen (1): Amphotericin B deoxycholate AND Flucytosine for 2 weeks, followed by Fluconazole for 8 weeks
- Preferred regimen (2): Amphotericin B lipid complex AND Flucytosine for 2 weeks, followed by Fluconazole for 8 weeks
- Preferred regimen (3): Amphotericin B deoxycholate AND Flucytosine for 6–10 weeks, followed by Fluconazole for 8 weeks
- Note: Consider placement of lumbar drain or VP shunt.
- Histoplasma capsulatum
- Preferred regimen: Amphotericin B liposomal for 4–6 weeks, followed by Itraconazole for at least 1 year and until resolution of CSF abnormalities
- Protozoa
- Acanthamoeba
- Preferred regimen (1): Trimethoprim-Sulfamethoxazole AND Rifampin AND Ketoconazole
- Preferred regimen (2): Fluconazole AND Sulfadiazine AND Pyrimethamine
- Balamuthia mandrillaris
- Preferred regimen: (Azithromycin OR Clarithromycin) AND Pentamidine AND Flucytosine AND Fluconazole AND Sulfadiazine AND (Thioridazine OR Trifluoperazine)
- Naegleria fowleri
- Preferred regimen: Amphotericin B (intravenous and intrathecal) AND Rifampin AND (Azithromycin OR Sulfisoxazole OR Miconazole)
- Plasmodium falciparum
- Preferred regimen: Quinine OR Quinidine OR Artesunate OR Artemether
- Alternative regimen (1): Atovaquone-Proguanil
- Alternative regimen (2): Exchange transfusion (for > 10% parasitemia or cerebral malaria)
- Toxoplasma gondii
- Preferred regimen: Pyrimethamine AND Sulfadiazine OR Clindamycin
- Alternative regimen (1): Trimethoprim-sulfamethoxazole
- Alternative regimen (2): Pyrimethamine AND (Atovaquone OR Clarithromycin OR Azithromycin OR Dapsone
- Trypanosoma brucei gambiense (West African trypanosomiasis)
- Preferred regimen: Eflornithine OR Melarsoprol
- Trypanosoma brucei rhodesiense (East African trypanosomiasis)
- Preferred regimen: Melarsoprol
- Helminths
- Baylisascaris procyonis
- Preferred regimen: Albendazole AND Diethylcarbamazine AND Corticosteroids
- Gnathostoma
- Preferred regimen: Albendazole OR Ivermectin
- Taenia solium (cysticercosis)
- Preferred regimen: Albendazole AND Corticosteroids
- Alternative regimen: Praziquantel AND Corticosteroids
- Prion
- Human transmissible spongiform encephalopathy
- Preferred regimen: supportive
- ↑ Tunkel, Allan R.; Glaser, Carol A.; Bloch, Karen C.; Sejvar, James J.; Marra, Christina M.; Roos, Karen L.; Hartman, Barry J.; Kaplan, Sheldon L.; Scheld, W. Michael; Whitley, Richard J.; Infectious Diseases Society of America (2008-08-01). "The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 47 (3): 303–327. doi:10.1086/589747. ISSN 1537-6591. PMID 18582201.